CA-PATIENT-SAFETY
The Patient Safety Movement Foundation (PSMF) , a global non-profit committed to achieving zero preventable patient harm and death across the globe by 2030, today announced Michael A.E. Ramsay, MD, FRCA as its new chief executive officer. Following his appointment, Mike Durkin, OBE, MBBS, FRCA, FRCP, DSc will assume Ramsay’s previous role as chairman. Under their leadership, the organization looks forward to continuing to improve patient safety around the globe.
Dr. Ramsay assumes the role from former CEO, David B. Mayer, MD, who played a pivotal part in helping the organization launch the inaugural #UniteForSafeCare event. During his tenure, Mayer also introduced a new commitment model making it easier for hospitals and healthcare organizations to prioritize patient safety and was a driving force behind the call for a Patient Safety Moonshot .
“We are grateful for all of Dr. Mayer’s efforts over the past three years and believe that Dr. Ramsay is the right leader for this next chapter,” stated Ariana Longley, MPH, chief operating officer at the Patient Safety Movement Foundation. “The leadership, expertise, passion and global connections that Dr. Ramsay and Dr. Durkin bring to the organization position us well to achieve our audacious goals.”
“I am honored to be appointed as CEO,” said Dr. Ramsay. “The last year and a half has put a spotlight on the gaps in our healthcare system. I am excited to work in lockstep with the strong leadership and team at PSMF to forge partnerships that actively promote change, develop and disseminate patient safety education material and create public demand for safe and highly reliable healthcare.”
Prior to being named CEO, Dr. Ramsay was an early member of PSMF set up by Joe Kiani in 2012 and most recently served as chairman of PSMF since 2020. He brings extensive experience serving as chairman emeritus of the Department of Anesthesiology and Pain Management at Baylor University Medical Center in Dallas, Texas. He is also a professor at the Texas A&M Health Science Center and holds a clinical professorship in anesthesiology at the University of Texas Southwestern Medical School. Ramsay was president of the Baylor Scott and White Research Institute from 2000 to 2020, where the focus was on developing cancer vaccines and early cancer biomarkers. He is past director of anesthesia for the liver transplant program at Baylor and has personally provided anesthesia for over 1,000 liver transplant recipients. He has also held roles in numerous groups, including a current member of the Baylor University Medical Center board of trustees, past president of the International Liver Transplantation Society, committee member of the United Network for Organ Sharing and a member of the American Society of Anesthesiologists committee on transplant anesthesia and “Failure to Rescue: Post-operative Respiratory Depression” workgroup of the PSMF. He was born in Dublin, Ireland, went to Brentwood School in the UK and trained in medicine at The Royal London Hospital. Ramsay was recruited by Baylor University Medical Center in Dallas, Texas in 1976.
Dr. Durkin has been a member of PSMF since 2012 and is transitioning from vice chairman to chairman. Durkin brings 30 years of experience in medical management and leadership to his role with PSMF. He currently maintains positions as the visiting professor and senior advisor on patient safety policy and leadership of the NIHR Patient Safety Translational Research Centre at the Institute of Global Health Innovation at Imperial College London and as associate non-executive director at NHS Resolution. Passionate about patient safety, he played an integral role in the assembly of the Berwick Advisory Board in 2013 to advise on creating conditions to improve the safety of patients in England. Durkin was commissioned by the secretary of state for health to chair an expert advisory group that led to the establishment of the Healthcare Safety Investigation branch. He also headed the development of the Ministerial Inter-Governmental Summits on Patient Safety held in the UK (2016), Germany (2017), Japan (2018) and Saudi Arabia (2019). Outside of PSMF, he has served as the national director of patient safety for England’s NHS, executive medical director at Gloucestershire Royal Hospital and held successive executive medical director positions for England’s strategic health authorities culminating as the medical director of the NHS for the South of England supporting a population of 16 million people. Prior to these roles, he held attending, research and teaching positions in cardiovascular anesthesia and critical care at London, Yale and Bristol universities.
“I am honored to continue to work with the Patient Safety Movement Foundation in this role,” states Durkin. “We have made great progress but are now at a time when we must issue a call to urgent and sustained action for all patients and families as well as political and healthcare leaders, nurses, doctors, pharmacists and therapists of every dimension to continue to educate and empower others to help us reach our goal of zero.”
About the Patient Safety Movement Foundation: Each year, more than 200,000 people die in U.S. hospitals and more than three million globally as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005331/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference15.1.2026 01:40:00 CET | Press release
Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studiesHaving secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), SBE303, Samsung Bioepis’ novel antibody-drug conjugate (ADC) engineered to target Nectin-4, will enter into the Phase 1 first-in-human clinical trial this yearSamsung Bioepis plans to add one novel therapeutic candidate in clinical study every year Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114206458/en/ Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings "2026 is a mon
Most Delivered Light-Entry Jet Cessna Citation M2 Gen2 With Garmin Autothrottles Enters Into Service, Bringing Greater Control and Precision to Pilots14.1.2026 20:30:00 CET | Press release
The Cessna Citation M2 Gen2 with Garmin Autothrottles recently entered into service. Certified by the Federal Aviation Administration in October 2025, the integration of Garmin’s Autothrottle system in the Citation M2 Gen2 further supports the most delivered light-entry jet’s capabilities by bringing greater control and precision to pilots. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114646844/en/ Most delivered light-entry jet Cessna Citation M2 Gen2 with Garmin Autothrottles enters into service, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “We continue to invest in our products to provide customers with the best aviation experience in the world," said Lannie O’Bannion, senior vice president, Sales & Marketing. “The M2 Gen2 leads its segment as the most delivered
TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis14.1.2026 18:30:00 CET | Press release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/ Fachklinik Schömberg Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents
AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 16:00:00 CET | Press release
Analysis finds AI could add 30 trillion liters of annual water demand, but targeted reuse and digital infrastructure investments can substantially offset demand and protect communities The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data ce
ACCELQ Crowned Leader and Customer Favorite in The Forrester Wave™ for Autonomous Testing Platforms14.1.2026 16:00:00 CET | Press release
Agentic Test Automation Pioneer Caps Record-Breaking Year of Growth and "AI-Based Engineering Solution of the Year" Honors Forrester has named ACCELQ a Leader in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025. This marks the third consecutive Wave in which ACCELQ has been recognized as a Leader. Notably, this evaluation placed strong emphasis on generative AI innovation and real-world customer adoption. ACCELQ received the highest scores for both capabilities and vision and was the only platform to be recognized as a Customer Favorite, earning a "double halo" for exceptional customer endorsement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113112861/en/ ACCELQ recognized as a Leader and Customer Favorite in The Forrester Wave™️: Autonomous Testing Platforms, Q4 2025, validating its agentic, GenAI-embedded testing vision. According to the Forrester report, ACCELQ received the highest score among all evaluate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
